AGM/EGMJun 5, 2026, 08:01 AM
MBX Biosciences Elects Two Class II Directors; Ratifies Auditor
AI Summary
MBX Biosciences, Inc. held its 2026 annual meeting of stockholders on June 4, 2026. During the meeting, stockholders approved the election of Patrick J. Heron and Edward T. Mathers as Class II directors, each to serve a three-year term until the 2029 annual meeting. Additionally, stockholders ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- MBX Biosciences held its 2026 annual meeting of stockholders on June 4, 2026.
- Stockholders approved the election of Patrick J. Heron as a Class II director with 35,007,623 votes For.
- Stockholders approved the election of Edward T. Mathers as a Class II director with 31,983,223 votes For.
- Both Class II directors will serve a three-year term ending at the 2029 annual meeting.
- Stockholders ratified the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2026 with 43,713,693 votes For.
- As of April 10, 2026, there were 47,570,485 shares of common stock outstanding.
Price Impact
More from MBX